HC Wainwright Has Positive Outlook of NRXP FY2024 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – HC Wainwright raised their FY2024 EPS estimates for NRx Pharmaceuticals in a report issued on Monday, November 25th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings per share of ($1.75) for the year, up from their prior estimate of ($3.25). HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2024 earnings at ($0.20) EPS and FY2025 earnings at ($0.08) EPS.

A number of other brokerages also recently issued reports on NRXP. EF Hutton Acquisition Co. I raised NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st. Ascendiant Capital Markets upped their target price on NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a research report on Thursday, September 12th.

NRx Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ:NRXP opened at $1.29 on Wednesday. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $7.33. The company’s 50 day moving average price is $1.38 and its two-hundred day moving average price is $2.14. The firm has a market cap of $15.60 million, a PE ratio of -0.61 and a beta of 1.27.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned approximately 1.33% of NRx Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.